What Insurance Does a Life Sciences Company Need During Due Diligence?

By the time an acquirer or institutional investor opens the diligence binder on a life sciences company, the insurance program is already being scored against deal terms. Gaps are not noted and forgiven; they become price adjustments, escrow holdbacks, reps and warranties insurance requirements, or special conditions in the closing documents. Companies that have not reviewed their program before the process starts negotiate from a weaker position, because the buyer’s counsel finds the gaps and prices them in. The cheaper version is to find them first.

What the Diligence Process Actually Looks At

Buyer counsel and investor diligence teams work from a standard insurance checklist that scales to the deal but does not shrink to it. The checklist includes the policy schedule (every line and limit currently in force), the carriers and their financial strength ratings, the retroactive dates on every claims-made policy, any open or recently closed claims, the contractual insurance requirements the company has agreed to with customers and partners, and the gaps between what the contracts require and what the policies actually provide. For a life sciences company specifically, the checklist also asks about products liability for cleared or in-trial products, clinical trial liability for any active or recent studies, cyber and HIPAA coverage scaled to actual PHI volume, and the management liability tower if a board is in place.

None of this is a surprise once the process is in motion. The surprise is that most companies do not run the same checklist on themselves before the buyer arrives, and the first time they see the gaps is in a redline from the other side.

The Gaps That Most Often Reshape the Deal

Three categories drive the most deal friction. The first is products and clinical trial coverage seams: a clinical-to-commercial gap, a missing tail or retroactive date, or a program that does not respond to a region the company sells into. Each of these is hard to fix at close, and buyers price the uncertainty into the deal. The seam dynamic is the one in how a clinical trial reshapes the device insurance program, and it is exactly the kind of finding that lands on the diligence list.

The second is contractual mismatch. Customers and partners frequently require specific insurance terms, often additional insured status with a particular scope, primary and non-contributory language, or waiver of subrogation. A company that has signed those contracts without confirming the policy actually delivers what was promised carries a breach risk on every one of them, and diligence surfaces it. The signing-day version of this is described in an additional insured endorsement clinical lab and in what insurance you need before signing a distribution agreement, and the diligence-stage version is the same problem at a different moment.

The third is management liability. A D&O program that is too thin, too narrowly worded, or carries entity-versus-individual coverage seams becomes a flashpoint when the buyer’s counsel asks about Side A, Side B, and Side C scope, change-of-control language, and run-off requirements. A company that has never priced run-off discovers what it costs during the negotiation, and the seller usually pays. The trigger for putting D&O in place at all is mapped in medical device company directors and officers insurance, and that program meeting the diligence standard is a separate question from having it.

How Reps and Warranties Insurance Enters the Conversation

Above a certain deal size, reps and warranties insurance becomes a transaction tool rather than a curiosity. The R&W policy backs the seller’s representations in the purchase agreement and lets the buyer collect from the carrier rather than from the seller for breaches discovered post-close. Underwriters for R&W policies do their own diligence on the target’s insurance program, and gaps the buyer might have lived with become exclusions on the R&W policy. The R&W exclusion list then becomes a deal point in its own right, with the seller asked to retain risk the R&W carrier declined.

Companies that walk into the R&W underwriting with a clean, contemporaneous program review have fewer exclusions and a smoother negotiation. Companies that have not done the review walk into a list of exclusions written by an underwriter who has never met them.

What to Do Before the Process Starts

The cheap version of the diligence review is to run it on yourself six months before any transaction is in view. Pull the policy schedule, lay it next to the customer and partner contracts, identify the gaps between what is required and what is in force, and close them at renewal rather than at close. Confirm retroactive dates and prior acts on every claims-made policy. Confirm the management liability tower has change-of-control and run-off language that does not surprise the next conversation.

The work is the same work that builds a defensible program in steady state. The difference is that doing it before the buyer’s counsel does is the version that protects the deal value, the seller’s reserve, and the founder’s bandwidth. A specialty review through Tower Street Insurance can run a diligence-grade review of a life sciences company’s program against the contracts in force, the claims history, and the buyer-side checklist, before the process opens rather than after.